Stately Bio

Stately Bio is a pioneering biotechnology firm specializing in regenerative medicine, utilizing advanced machine learning technology for innovative cell imaging solutions that enhance therapeutic developments. Founded in 2022 in Palo Alto, US, Stately Bio focuses on regenerative medicine with a unique machine learning cell imaging platform. The firm's operations have expanded to include significant partnerships with top-tier research institutions and biotechnology companies globally. The founder, whose background includes significant experience in the biotech sector, has a vision for advancing cell therapy innovations.

Stately Bio has successfully completed 2 significant funding rounds, with the most recent being a Seed round in May 2025, raising USD 12. 000 mn led by AIX Ventures and supported by various notable investors including Dimension Management and Village Global. Stately Bio specializes in pioneering regenerative medicine through its advanced machine learning (ML) cell imaging platform. The company’s core products leverage patented ML technology to perform live-cell, label-free imaging, enabling the measurement of cell identity, behavior, and maturation without compromising cell viability.

These capabilities serve the end use cases of enhancing the discovery and development of novel stem cell-derived therapies, addressing significant challenges in cell therapy innovation. Stately Bio collaborates with leading institutions and companies within the regenerative medicine sector, targeting markets globally, including North America and Europe. Its clientele consists primarily of healthcare organizations, research institutions, and biotechnology companies that require advanced cell imaging solutions to propel their therapeutic developments. Stately Bio operates on a revenue model that incorporates partnerships and direct collaborations with top-tier research institutions and biotechnology firms.

The business transactions primarily involve service agreements wherein clients utilize Stately Bio's proprietary ML imaging technology for their cell therapy research and development projects. These collaborations are structured as contract-based arrangements, often featuring tiered pricing depending on the scope and duration of the partnership. Specific details regarding pricing plans for individual services or flagship offerings have not been disclosed; however, the company's revenue streams are likely derived from these strategic partnerships that facilitate innovative advancements in regenerative medicine. Stately Bio plans to leverage the USD 12.

000 mn raised in Seed funding to scale its platform technology and mature its internal pipeline of stem cell-derived therapeutics. The company is set to expand its operations into new markets, specifically targeting Europe and Asia by the end of 2026. Additionally, Stately Bio is developing new products that enhance its existing ML imaging technology, with plans for a product launch expected in late 2025.